| Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR task force on good research practices—Modeling studies MC Weinstein, B O'Brien, J Hornberger, J Jackson, M Johannesson, ... Value in health 6 (1), 9-17, 2003 | 1363 | 2003 |
| The NICE cost-effectiveness threshold: what it is and what that means C McCabe, K Claxton, AJ Culyer Pharmacoeconomics 26, 733-744, 2008 | 974 | 2008 |
| Neonatal screening for inborn errors of metabolism: cost, yield and outcome. RJ Pollitt, A Green, CJ McCabe, A Booth, NJ Cooper, JV Leonard, ... Health technology assessment (Winchester, England) 1 (7), i-iv, 1, 1997 | 323 | 1997 |
| Measuring the mental health status of a population: A comparison of the GHQ–12 and the SF–36 (MHI–5) CJ McCabe, KJ Thomas, JE Brazier, P Coleman The British Journal of Psychiatry 169 (4), 517-521, 1996 | 323 | 1996 |
| An international, multicentre, prospective, randomised, controlled, unblinded, parallel-group trial of robotic-assisted versus standard laparoscopic surgery for the curative … FJ Collinson, DG Jayne, A Pigazzi, C Tsang, JM Barrie, R Edlin, C Garbett, ... International journal of colorectal disease 27, 233-241, 2012 | 320 | 2012 |
| Orphan drugs and the NHS: should we value rarity? C McCabe, K Claxton, A Tsuchiya Bmj 331 (7523), 1016-1019, 2005 | 293 | 2005 |
| 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial HM Earl, L Hiller, AL Vallier, S Loi, K McAdam, L Hughes-Davies, ... The Lancet 393 (10191), 2599-2612, 2019 | 292 | 2019 |
| Value based pricing for NHS drugs: an opportunity not to be missed? K Claxton, A Briggs, MJ Buxton, AJ Culyer, C McCabe, S Walker, ... Bmj 336 (7638), 251-254, 2008 | 282 | 2008 |
| Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence A Culyer, C McCabe, A Briggs, K Claxton, M Buxton, R Akehurst, ... Journal of health services research & policy 12 (1), 56-58, 2007 | 242 | 2007 |
| Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others JMS Bartlett, J Bayani, A Marshall, JA Dunn, A Campbell, C Cunningham, ... JNCI: Journal of the National Cancer Institute 108 (9), djw050, 2016 | 214 | 2016 |
| Setting global standards for stem cell research and clinical translation: the 2016 ISSCR guidelines GQ Daley, I Hyun, JF Apperley, RA Barker, N Benvenisty, AL Bredenoord, ... Stem cell reports 6 (6), 787-797, 2016 | 211 | 2016 |
| Marketing of unproven stem cell–based interventions: a call to action D Sipp, T Caulfield, J Kaye, J Barfoot, C Blackburn, S Chan, M De Luca, ... Science translational medicine 9 (397), eaag0426, 2017 | 172 | 2017 |
| Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems T Stafinski, CJ McCabe, D Menon Pharmacoeconomics 28, 113-142, 2010 | 170 | 2010 |
| Public healthcare resource allocation and the Rule of Rescue R Cookson, C McCabe, A Tsuchiya Journal of medical ethics 34 (7), 540-544, 2008 | 167 | 2008 |
| Using rank data to estimate health state utility models C McCabe, J Brazier, P Gilks, A Tsuchiya, J Roberts, A O’Hagan, ... Journal of health economics 25 (3), 418-431, 2006 | 152 | 2006 |
| Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment DM Pickin, CJ McCabe, LE Ramsay, N Payne, IU Haq, WW Yeo, ... Heart 82 (3), 325-332, 1999 | 134 | 1999 |
| Cost effectiveness modelling for health technology assessment: a practical course R Edlin, C McCabe, C Hulme, P Hall, J Wright Springer International Publishing, 2015 | 128 | 2015 |
| Value-based reimbursement decisions for orphan drugs: a scoping review and decision framework M Paulden, T Stafinski, D Menon, C McCabe Pharmacoeconomics 33, 255-269, 2015 | 109 | 2015 |
| Access with evidence development schemes: a framework for description and evaluation CJ McCabe, T Stafinski, R Edlin, D Menon Pharmacoeconomics 28, 143-152, 2010 | 106 | 2010 |
| Health state values for the HUI 2 descriptive system: results from a UK survey C McCabe, K Stevens, J Roberts, J Brazier Health economics 14 (3), 231-244, 2005 | 105 | 2005 |
